Lipodystrophy

Lipodystrophy features

• 

  Body fat changes in people with HIV: a clinical review

  This article reviews the antiretroviral side-effect of lipoatrophy (fat loss) in resource-limited settings....

  From:HIV & AIDS treatment in practice

• 

  How frequently are ARV side-effects being seen in resource-limited settings, and how are they dealt with?

  Review of major side-effects of first-line antiretroviral regimens in resource-limited settings, and what can be done to reduce or avoid them....

  From:HIV & AIDS treatment in practice

Lipodystrophy news from aidsmap

• Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers

  Reductions in visceral adiposity achieved with tesamorelin therapy are associated with improvements in some key metabolic parameters, according to a study published in the online edition of Clinical Infectious Diseases. The HIV-positive patients who responded to the therapy had ...

  30 April 2012 | Michael Carter

• Lipoatrophy common in children receiving d4T in South Africa

  Exposure to d4T (stavudine) among young children in sub-Saharan Africa remains the greatest risk factor for lipodystrophy syndrome (that includes lipoatrophy and lipohypertrophy) for a significant proportion of children, urgently highlighting the need for early detection of abnormal body fat ...

  07 March 2012 | Carole Leach-Lemens

• Fat accumulation linked to cognitive impairment in patients with HIV

  Central fat accumulation is associated with an increased risk of neurocognitive impairment for HIV-positive patients, according to a study published in the February edition of Neurology. Overall 40% of patients in the study were diagnosed with impairment and increased waist circumference ...

  24 February 2012 | Michael Carter

• Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

  Raltegravir (Isentress)-based treatment appears to have a more favourable impact on fat accumulation and bone metabolism compared to therapy based on a ritonavir-boosted protease inhibitor, according to Spanish research published in the online edition of AIDS. The study involved ...

  28 November 2011 | Michael Carter

• Diseases of ageing occurring 10 to 15 years earlier in patients with HIV

  The diseases of ageing develop earlier in patients with HIV than in the general population, Italian investigators report in the online edition of Clinical Infectious Diseases. “Our findings suggest that an aggressive approach to the screening, diagnosis, and treatment of ...

  20 October 2011 | Michael Carter

• Waist circumference and triglycerides: simple measures of increased cardiovascular risk for patients with HIV

  Measuring waist circumference and triglyceride levels may be an easy way of identifying which HIV-positive patients have an increased risk of cardiovascular disease, according to research published in PLoS One. Italian investigators found a consistent and significant relationship between ...

  10 October 2011 | Michael Carter

• Kivexa and Truvada-based combinations associated with long-term gains in limb fat, not fat loss

  Modern antiretroviral regimens based on Kivexa and Truvada are associated with long-term gains in limb fat, US investigators report in the July 15th edition of Clinical Infectious Diseases. After 96 weeks of therapy limb fat levels had increased by approximately ...

  27 June 2011 | Michael Carter

• Amount of fat around the heart can predict cardiovascular risk for patients with HIV

  Measuring the volume of fat around the heart can help predict which HIV-positive patients have an increased risk of cardiovascular disease, an Italian study published in the online edition of AIDS suggests. Investigators used CT scans to monitor ...

  27 April 2011 | Michael Carter

• Young adults who were infected at birth: the complexities of lifelong HIV are increasingly apparent

  Although 85% of young adults who take antiretroviral therapy have an undetectable viral load, the complexities and complications of lifelong HIV infection are becoming increasingly apparent, researchers told the British HIV Association conference in Bournemouth last week. Rates of hospital admissions, ...

  11 April 2011 | Roger Pebody

• Decreased limb muscle and increased abdominal fat linked to higher mortality in people with HIV

  HIV-positive people who lose muscle mass in their arms and legs whilst gaining abdominal fat have a higher likelihood of death, according to findings from the FRAM study presented on Tuesday at the 18th Conference on Retroviruses and Opportunistic Infections ...

  02 March 2011 | Liz Highleyman

More news

Lipodystrophy news selected from other sources

• Why it's time to say goodbye to stavudine...everywhere

  Concerns about a proposed comparative trial of 40mg and 20mg (low-dose) stavudine in South Africa.

  16 April 2012 | South African Journal of HIV Medicine

• Face fillers and dental work—caution needed

  Reconstructive surgery to deal with the loss of subcutaneous fat in the face involved injection of facial fillers. One product used was polyalkylimide gel (PAIG, Bio-Alcamid). However, reports began to emerge from Western Europe of inflammation and infections in both HIV-negative and HIV-positive people with Bio-Alcamid implants. 

  25 January 2012 | CATIE

• Theratechnologies to discontinue COPD clinical program and focus on lipodystrophy

  The Company will now focus its efforts on tesamorelin's significant potential for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Currently, applications for this indication are under review with regulatory agencies in Europe, Argentina, Brazil, Canada, Israel and Mexico.

  08 December 2011 | Theratechnologies press release

• Body Satisfaction Increased With Fat Gains in Prezista Study

  Although treatment experienced HIV-positive men and women had slightly greater gains in trunk fat after switching to a new regimen containing Prezista (darunavir), they also reported increased satisfaction with their bodies.

  17 June 2011 | AIDSMeds

• Theratechnologies seeks European marketing for lipodystrophy drug Tesamorelin

  Theratechnologies Inc. says it has applied to sell its lead drug tesamorelin in Europe. The drug is a treatment for excess abdominal fat in adult HIV-infected patients with lipodystrophy.

  07 June 2011 | Stock House

• What Lies Ahead: An Activist's View of Promising HIV Treatment Research

  After attending the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Mass., and following different areas of research, I decided to write down a list of advancements that really thrill and energize me as an educator and research advocate.

  31 March 2011 | The Body

• European regulator restricts use of d4T (stavudine, Zerit)

  In view of the side effects seen with the medicine, the CHMP recommended that the marketing authorisation for Zerit should be renewed with restrictions. The Committee recommended that, for both adults and children, it should be used for as short a time as possible and only when there are no appropriate alternatives.

  18 February 2011 | European Medicines Agency

• HIV Lipo Drug Egrifta Now Available; Financial Assistance Programs Open

  Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially available to people living with HIV and their health care providers, according to EMD Serono.

  27 January 2011 | AIDSMeds

• INDONESIA: Sex, not drug users, causing most new HIV infections in Bali

  Bali's dramatic increase of HIV prevalence among sex workers has changed the face of the epidemic on this famed tourist destination of 3.9 million local residents, NGOs say.

  03 January 2011 | IRIN Plus News

More news